EGFR and non-small cell lung carcinoma: Overall, novel biomarkers or therapeutics are urgently needed to predict prognosis or enhance the efficacy of immunotherapy in NSCLC patients harboring EGFR mutation, especially patients with LUAD, which accounts for approximately 40–50% of all NSCLC cases.